Free Trial

CME Group (CME) Stock Forecast & Price Target

CME Group logo
$221.17 -4.02 (-1.79%)
(As of 11/6/2024 ET)

CME Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
4
Hold
7
Buy
4

Based on 15 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 4 have given a sell rating, 7 have given a hold rating, and 4 have given a buy rating for CME.

Consensus Price Target

$222.73
0.71% Upside
According to the 15 analysts' twelve-month price targets for CME Group, the average price target is $222.73. The highest price target for CME is $258.00, while the lowest price target for CME is $180.00. The average price target represents a forecasted upside of 0.71% from the current price of $221.17.
Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

Sign Up

CME Analyst Ratings Over Time

TypeCurrent Forecast
11/8/23 to 11/7/24
1 Month Ago
10/9/23 to 10/8/24
3 Months Ago
8/10/23 to 8/9/24
1 Year Ago
11/8/22 to 11/8/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
4 Sell rating(s)
4 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$222.73$217.71$212.64$220.00
Forecasted Upside0.71% Upside-1.79% Downside2.89% Upside3.51% Upside
Consensus Rating
Hold
Reduce
Hold
Moderate Buy

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CME Group Stock vs. The Competition

TypeCME GroupFinance CompaniesS&P 500
Consensus Rating Score
2.00
2.47
2.50
Consensus RatingHoldHoldHold
Predicted Upside0.71% Upside9.83% Upside7.32% Upside
News Sentiment Rating
Positive News

See Recent CME News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/28/2024Piper Sandler
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$240.00 ➝ $250.00+10.55%
10/24/2024Oppenheimer
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$245.00 ➝ $258.00+12.64%
10/24/2024Royal Bank of Canada
4 of 5 stars
A. Sabadra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$235.00 ➝ $235.00+2.60%
10/24/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$250.00 ➝ $255.00+12.12%
10/24/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$219.00 ➝ $231.00+1.70%
10/17/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$210.00 ➝ $233.00+2.02%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Clinch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$244.00+10.04%
10/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$195.00 ➝ $198.00-11.89%
10/3/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$177.00 ➝ $180.00-19.49%
9/26/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Katz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$221.00+1.60%
8/15/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$193.00 ➝ $200.00-2.59%
7/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$187.00 ➝ $191.00-3.65%
7/25/2024Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$212.00 ➝ $213.00+7.98%
4/25/2024Rosenblatt Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell ➝ Sell$185.00 ➝ $187.00-12.04%
3/6/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$225.00 ➝ $245.00+12.27%
2/7/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$192.00 ➝ $198.00+13.30%
1/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$226.00 ➝ $220.00+29.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:48 AM ET.


Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 20, 2024. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CME Group Inc.:

  • CME Group Inc. has a strong financial performance with a consistent increase in revenue and earnings per share over recent quarters, indicating a stable and profitable business.
  • Analysts have raised the price target for CME Group Inc., suggesting positive growth potential and confidence in the company's future performance.
  • The company pays a quarterly dividend with a dividend yield of 2.11%, providing investors with a steady income stream.
  • CME Group Inc. has a low debt-to-equity ratio of 0.10, indicating a healthy financial structure and lower financial risk.
  • The stock price of CME Group Inc. has shown resilience and stability, trading within a reasonable range, which can be attractive to risk-averse investors.

CME Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CME Group Inc. for these reasons:

  • Several analysts have issued sell ratings on CME Group Inc., indicating concerns about the company's future performance or market conditions.
  • Despite some price target increases, there are also underperform ratings on the stock, suggesting potential challenges or weaknesses in the company's operations.
  • The stock has a beta of 0.55, indicating lower volatility compared to the market, which may limit potential returns for more aggressive investors seeking higher growth opportunities.
  • There is a consensus rating of "Hold" on CME Group Inc., implying a lack of strong buy signals from analysts, potentially signaling a stagnant stock performance in the near term.
  • Investors should consider the company's price-to-earnings ratio of 25.28 and price-to-earnings-growth ratio of 8.74 to assess whether the stock is currently overvalued relative to its growth prospects.

CME Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $222.73, with a high forecast of $258.00 and a low forecast of $180.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 4 sell ratings, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CME, but not buy additional shares or sell existing shares.

According to analysts, CME Group's stock has a predicted upside of 0.71% based on their 12-month stock forecasts.

Over the previous 90 days, CME Group's stock had 2 downgrades by analysts.

Analysts like CME Group less than other "finance" companies. The consensus rating score for CME Group is 2.00 while the average consensus rating score for "finance" companies is 2.48. Learn more on how CME compares to other companies.


This page (NASDAQ:CME) was last updated on 11/7/2024 by MarketBeat.com Staff
From Our Partners